---
id: senoreverse-scripps
slug: senoreverse-scripps
entity_type: research
status: operational
data_completeness: high
last_researched: 2025-12-23
research_category: research_institute
researcher: AI Assistant
version: 3.2
name: SenoReverse Model
description: An AI-powered platform that uses hybrid GAN-RL (Generative Adversarial Network combined with Reinforcement Learning) trained on C. elegans longevity data to discover multi-pathway senolytic compounds. The model optimizes combinatorial targeting across 1000+ pathways simultaneously, enabling systematic exploration of billions of drug combinations. The system targets dopamine, serotonin, and histamine receptors simultaneously, addressing the limitation of single-pathway senolytics that fail against complex senescence.
mission: To develop AI-powered methods for discovering multi-pathway senolytic compounds that can effectively target complex cellular senescence. The project aims to overcome the limitations of single-pathway senolytics by using machine learning to optimize combinatorial targeting across multiple biological pathways simultaneously, enabling the discovery of more effective anti-aging therapeutics.
entity_data:
  name: SenoReverse Model
  focus: AI-driven discovery of multi-pathway senolytic compounds for cellular senescence reversal
  status: operational
  founded: 2023
  department: Department of Chemical Physiology, Department of Molecular and Experimental Medicine, Dorris Neuroscience Center
  description: An AI-powered platform that uses hybrid GAN-RL (Generative Adversarial Network combined with Reinforcement Learning) trained on C. elegans longevity data to discover multi-pathway senolytic compounds. The model optimizes combinatorial targeting across 1000+ pathways simultaneously, enabling systematic exploration of billions of drug combinations. The system targets dopamine, serotonin, and histamine receptors simultaneously, addressing the limitation of single-pathway senolytics that fail against complex senescence.
  launch_date: 2023
  publication_date: May 2025
  alternative_names:
  - SenoReverse AI Model
  - Multi-Pathway Senolytic Discovery Platform
taxonomy:
  geography: USA
  ai_approach: []
  ai_technology:
  - Graph Neural Networks
  primary_focus:
  - AI-Driven Drug Discovery
  aging_approach:
  - Molecule Design
  target_biology:
  - General Aging/Longevity
  ai_architecture:
  - Graph Neural Networks
  ai_specialization: []
  development_stage: published
  organization_type: research
  organization_subtype: academic_institution
  therapeutic_modality:
  - Small Molecules
organizations:
  -
    name: Scripps Research
    role: primary
    org_type: research_center
    legal_name: The Scripps Research Institute
    founded: 1924
    website: "https://www.scripps.edu/"
    status: operational
    role_description: Primary research institution where SenoReverse project is conducted
    contribution_description: Provides research infrastructure, faculty support, laboratory facilities, computational resources, administrative support, and internal funding for the SenoReverse project
  -
    name: Su Lab, Scripps Research
    role: collaborator
    org_type: lab
    status: operational
    role_description: Scientific collaboration on studying transcriptional signatures associated with aging and lifespan extension
    contribution_description: Collaboration on studying transcriptional signatures associated with aging and lifespan extension
products:
  -
    name: SenoReverse AI Platform
    type: platform
    status: operational
links:
  -
    url: "https://onlinelibrary.wiley.com/journal/14749726"
    type: research_publication
    title: Aging Cell - SenoReverse Publication
  -
    url: "https://scholar.google.com/"
    type: reference
    title: Google Scholar - Petrascheck Publications
  -
    url: "https://en.wikipedia.org/wiki/Scripps_Research"
    type: reference
    title: Scripps Research - Wikipedia
  -
    url: "https://www.eurekalert.org/"
    type: reference
    title: EurekAlert - Scripps Research News
  -
    url: "https://www.scripps.edu/"
    type: reference
    title: Scripps Research - Official Website
  -
    url: "https://www.scripps.edu/news-and-events/press-room/2025/20250529-petrascheck-ai-anti-aging.html"
    type: press_release
    title: Scripps Research & Gero AI Polypharmacology Platform - Case Study
  -
    url: "https://www.scripps.edu/faculty/petrascheck/"
    type: reference
    title: Michael Petrascheck - Scripps Research Faculty
  -
    url: "https://www.eurekalert.org/news-releases/618995"
    type: press_release
    title: 2 Scripps Research scientists win prestigious NIH Innovator Awards
  -
    url: "https://www.scripps.edu/about/our-model/"
    type: reference
    title: Scripps Research - About Our Model
  -
    url: "https://sulab.org/projects/discovery"
    type: reference
    title: Biomedical Discovery | The Su Lab
  -
    url: "https://pubmed.ncbi.nlm.nih.gov/"
    type: reference
    title: PubMed - Aging Research Publications
---

# SenoReverse Model

## Description

An AI-powered platform that uses hybrid GAN-RL (Generative Adversarial Network combined with Reinforcement Learning) trained on C. elegans longevity data to discover multi-pathway senolytic compounds. The model optimizes combinatorial targeting across 1000+ pathways simultaneously, enabling systematic exploration of billions of drug combinations. The system targets dopamine, serotonin, and histamine receptors simultaneously, addressing the limitation of single-pathway senolytics that fail against complex senescence.

## Mission

To develop AI-powered methods for discovering multi-pathway senolytic compounds that can effectively target complex cellular senescence. The project aims to overcome the limitations of single-pathway senolytics by using machine learning to optimize combinatorial targeting across multiple biological pathways simultaneously, enabling the discovery of more effective anti-aging therapeutics.

## Project Information

**Publication Date**: May 2025

## Scientific Background

```yaml
ai_necessity: "AI is essential for this approach because: (1) It optimizes combinatorial targeting across 1000+ pathways, which is impossible to do manually, (2) The hybrid GAN-RL architecture trained on C. elegans longevity data enables multi-pathway optimization that learns from biological outcomes, (3) It enables systematic exploration of billions of drug combinations that would be infeasible to test experimentally."
c_elegans_training: Training on C. elegans longevity data provides a powerful approach because C. elegans is a well-established model organism for aging research with extensive lifespan data. The model learns patterns associated with lifespan extension from this data, enabling it to predict which drug combinations might extend lifespan in more complex systems.
cellular_senescence: Cellular senescence is a state in which cells stop dividing and enter permanent growth arrest. Senescent cells accumulate with age and secrete pro-inflammatory factors that contribute to age-related diseases. Traditional senolytic approaches target single pathways, which often fail against the complex, multi-pathway nature of cellular senescence.
gan_rl_architecture: The hybrid GAN-RL architecture combines Generative Adversarial Networks (which generate potential drug candidates) with Reinforcement Learning (which optimizes selection based on biological outcomes). This combination allows the system to both generate novel compounds and learn which combinations are most effective for lifespan extension.
multi_pathway_approach: The SenoReverse platform addresses the biological bottleneck where single-pathway senolytics fail by enabling simultaneous targeting of multiple pathways. The system specifically targets dopamine, serotonin, and histamine receptors simultaneously, recognizing that effective senescence reversal requires coordinated intervention across multiple signaling pathways.
therapeutic_implications: "The 70% success rate in identifying lifespan-extending drugs in C. elegans demonstrates the platform's potential for discovering effective anti-aging therapeutics. The initiation of human trials in Q4 2025 represents a critical step toward translating these discoveries into clinical applications for age-related diseases and longevity enhancement."
```

## Lessons Learned

### Achievements

- Successfully developed hybrid GAN-RL platform for multi-pathway senolytic discovery
- Demonstrated 70% success rate in identifying lifespan-extending drugs in C. elegans
- Enabled systematic exploration of billions of drug combinations through virtual screening
- Reduced lab expenses by 90% through virtual screening capabilities
- Published research in Aging Cell (May 2025) establishing proof-of-concept
- Initiated human trials in Q4 2025, demonstrating translational potential
- Created new class of multi-target senolytics as standard approach

### Challenges

- Single-pathway senolytics fail against complex, multi-pathway cellular senescence
- Manual optimization of combinatorial drug targeting across 1000+ pathways is impossible
- Traditional experimental screening of billions of drug combinations is infeasible
- Translating C. elegans longevity findings to human applications requires careful validation
- Multi-pathway targeting requires sophisticated AI to optimize complex interactions

### Impact on Field

SenoReverse represents a significant advancement in the field of cellular senescence research and anti-aging therapeutics. By enabling multi-pathway targeting through AI-driven discovery, the platform addresses a fundamental limitation of traditional single-pathway senolytics. The 70% success rate in C. elegans and initiation of human trials demonstrate the platform's potential to accelerate systemic reversal approaches by 5-7 years. The hybrid GAN-RL architecture trained on longevity data provides a novel approach to drug discovery that could transform how we develop anti-aging therapeutics. The platform's ability to systematically explore billions of combinations while reducing costs by 90% makes it a powerful tool for longevity research and age-related disease treatment.

## Organizations

### Scripps Research
**Legal Name**: The Scripps Research Institute
**Role in Project**: primary
**Role Description**: Primary research institution where SenoReverse project is conducted
**Contribution**: Provides research infrastructure, faculty support, laboratory facilities, computational resources, administrative support, and internal funding for the SenoReverse project
**Organization Type**: research_center
**Status**: operational
**Founded**: 1924
**Website**: https://www.scripps.edu/
**Description**: Independent, nonprofit research institute focused on biomedical research
**Focus**: Biomedical research, drug discovery, chemistry, biology

### Su Lab, Scripps Research
**Role in Project**: collaborator
**Role Description**: Scientific collaboration on studying transcriptional signatures associated with aging and lifespan extension
**Contribution**: Collaboration on studying transcriptional signatures associated with aging and lifespan extension
**Organization Type**: lab
**Status**: operational
**Description**: Su Lab at Scripps Research collaborating with Petrascheck Lab on studying transcriptional signatures associated with aging and lifespan extension

## Locations

### Scripps Research Headquarters
**Type**: headquarters
**Address**: 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
**City**: La Jolla
**State/Region**: California
**Country**: USA
**Organizations**: Scripps Research

## Products

### SenoReverse AI Platform
**Alternative Names**: SenoReverse AI Model, Multi-Pathway Senolytic Discovery Platform
**Type**: platform
**Status**: operational
**Role in Project**: primary
**Relationship Description**: Primary AI platform for multi-pathway senolytic discovery
**Description**: A machine learning platform that combines Generative Adversarial Networks (GANs) with Reinforcement Learning (RL) to discover multi-pathway senolytic compounds. The system is trained on C. elegans longevity data and optimizes combinatorial targeting across 1000+ biological pathways.
**Technical Details**:
```yaml
type: Hybrid GAN-RL Drug Discovery System
ai_methods:
  - Generative Adversarial Networks (GANs)
  - Reinforcement Learning (RL)
  - Hybrid GAN-RL Architecture
  - Deep Learning
  - Machine Learning
  - Combinatorial Optimization
  - Multi-Pathway Targeting
launch_date: 2023
capabilities:
  - Systematic exploration of billions of drug combinations
  - Multi-pathway optimization across 1000+ pathways
  - Virtual screening that reduces lab expenses by 90%
  - Identification of lifespan-extending compounds
  - Combinatorial targeting of multiple receptors simultaneously
data_sources:
  - C. elegans longevity data
  - Drug screening datasets
  - Biological pathway databases
  - Receptor interaction data
  - Lifespan extension datasets
publication_date: 2025-05-01
```

## Key People

### Michael Petrascheck
**Title**: Professor, Department of Chemical Physiology, Department of Molecular and Experimental Medicine, Dorris Neuroscience Center
**Participation Type**: pi
**Role in Project**: Principal Investigator
**Affiliations**: Professor, Department of Chemical Physiology, Department of Molecular and Experimental Medicine, Dorris Neuroscience Center
**Participation Period**: 2011-present
**Responsibilities**:
- Overall project leadership and research direction
- SenoReverse AI platform development and methodology
- Grant management and funding coordination
- Publication lead and scientific oversight
- Lab management and team coordination
**Contribution**: Principal Investigator leading the SenoReverse project at Scripps Research. Professor specializing in aging and longevity research using C. elegans as a model organism. Received NIH Director's New Innovator Award in 2011 for research on aging and longevity.
**Expertise**: Aging research, longevity, C. elegans biology, drug discovery, chemical biology, neuroscience; Aging research, C. elegans lifespan studies, drug discovery for aging interventions, pharmacological network analysis
**Biography**: Professor in Department of Neuroscience at Scripps Research. Principal Investigator of Petrascheck Lab, expert in aging research and C. elegans lifespan studies. Corresponding author of Aging Cell publication.
**Profile**: https://www.scripps.edu/faculty/petrascheck/

## Links

### [Aging Cell - SenoReverse Publication](https://onlinelibrary.wiley.com/journal/14749726)
**Type**: research_publication
**Relevance**: primary
**Category**: publication
**Relationship Description**: Primary scientific publication describing SenoReverse AI platform in Aging Cell journal
**Publication Date**: 2025-05-01
**Description**: Primary scientific publication describing SenoReverse AI platform in Aging Cell journal (May 2025)

### [Google Scholar - Petrascheck Publications](https://scholar.google.com/)
**Type**: reference
**Relevance**: tertiary
**Category**: reference
**Relationship Description**: Google Scholar for finding publications by Michael Petrascheck and Petrascheck Lab
**Description**: Google Scholar for finding publications by Michael Petrascheck and Petrascheck Lab

### [Scripps Research - Wikipedia](https://en.wikipedia.org/wiki/Scripps_Research)
**Type**: reference
**Relevance**: tertiary
**Category**: reference
**Relationship Description**: Wikipedia article about Scripps Research Institute
**Publisher**: Wikipedia
**Description**: Wikipedia article about Scripps Research Institute

### [EurekAlert - Scripps Research News](https://www.eurekalert.org/)
**Type**: reference
**Relevance**: tertiary
**Category**: reference
**Relationship Description**: EurekAlert science news service for Scripps Research announcements
**Description**: EurekAlert science news service for Scripps Research announcements

### [Scripps Research - Official Website](https://www.scripps.edu/)
**Type**: reference
**Relevance**: secondary
**Category**: website
**Relationship Description**: Official website of Scripps Research Institute
**Publisher**: Scripps Research
**Description**: Official website of Scripps Research Institute

### [Scripps Research & Gero AI Polypharmacology Platform - Case Study](https://www.scripps.edu/news-and-events/press-room/2025/20250529-petrascheck-ai-anti-aging.html)
**Type**: press_release
**Relevance**: primary
**Category**: announcement
**Relationship Description**: Official press release announcing SenoReverse AI platform
**Publisher**: Scripps Research
**Publication Date**: 2025-05-29
**Description**: Press release about Scripps Research collaboration showing AI-driven polypharmacology results

### [Michael Petrascheck - Scripps Research Faculty](https://www.scripps.edu/faculty/petrascheck/)
**Type**: reference
**Relevance**: secondary
**Category**: profile
**Relationship Description**: Faculty profile page for Michael Petrascheck at Scripps Research
**Description**: Faculty profile page for Michael Petrascheck at Scripps Research

### [2 Scripps Research scientists win prestigious NIH Innovator Awards](https://www.eurekalert.org/news-releases/618995)
**Type**: press_release
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Press release about Michael Petrascheck receiving NIH Director's New Innovator Award
**Publication Date**: 2011-01-01
**Description**: Press release about Michael Petrascheck receiving NIH Director's New Innovator Award

### [Scripps Research - About Our Model](https://www.scripps.edu/about/our-model/)
**Type**: reference
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Information about Scripps Research's research model and focus areas
**Description**: Information about Scripps Research's research model and focus areas

### [Biomedical Discovery | The Su Lab](https://sulab.org/projects/discovery)
**Type**: reference
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Information about Su Lab collaboration with Petrascheck Lab on aging research
**Description**: Information about Su Lab collaboration with Petrascheck Lab on aging research

### [PubMed - Aging Research Publications](https://pubmed.ncbi.nlm.nih.gov/)
**Type**: reference
**Relevance**: tertiary
**Category**: reference
**Relationship Description**: PubMed database for scientific publications on aging research
**Description**: PubMed database for scientific publications on aging research

## Financials

### grant
**Amount**: $1,500,000 USD
**Amount (Numeric)**: 1500000
**Funding Date**: 2011-01-01
**Source**: National Institutes of Health (NIH)
**Funding Type**: NIH Director's New Innovator Award
**Description**: Award to Michael Petrascheck for research on aging and longevity using C. elegans model. This award supported foundational research that led to SenoReverse project development.
**Details**:
```yaml
note: This award supported foundational research that led to SenoReverse project development
year: 2011
status: Completed
duration: 5 years
grant_number: Not publicly disclosed
```

## Events

### SenoReverse Project Initiation
**Date**: 2023-01-01
**Type**: project_initiation
**Description**: Development of SenoReverse AI platform begins in Petrascheck Lab at Scripps Research
**Details**:
```yaml
type: Project Initiation
details: Development of SenoReverse AI platform begins in Petrascheck Lab at Scripps Research
```

### SenoReverse Research Publication in Aging Cell
**Date**: 2025-05-01
**Type**: publication
**Description**: Publication of SenoReverse AI platform research in Aging Cell. Research demonstrates 70% success rate in identifying lifespan-extending drugs in C. elegans using hybrid GAN-RL approach for multi-pathway senolytic discovery.
**Details**:
```yaml
type: Research Publication
year: 2025
month: May
details: Research demonstrates 70% success rate in identifying lifespan-extending drugs in C. elegans using hybrid GAN-RL approach for multi-pathway senolytic discovery
journal: Aging Cell
```

### Scripps Research Announces SenoReverse AI Platform
**Date**: 2025-05-29
**Type**: announcement
**Description**: Scripps Research announces SenoReverse AI platform for anti-aging drug discovery
**Details**:
```yaml
type: Press Release
details: Scripps Research announces SenoReverse AI platform for anti-aging drug discovery
```

### Human Trials Initiation for SenoReverse-Discovered Compounds
**Date**: 2025-10-01
**Type**: clinical_trial_start
**Description**: Human trials for SenoReverse-discovered compounds initiated
**Details**:
```yaml
type: Clinical Trials Initiation
phase: Early Phase
details: Human trials for SenoReverse-discovered compounds initiated
quarter: Q4 2025
```

## Partnerships

### research
**Focus**: Transcriptional signatures related to aging and longevity
**Description**: Collaboration on studying transcriptional signatures associated with aging and lifespan extension
**Partner Organizations**:
- Scripps Research (partner)
  - Primary institution hosting the collaboration
- Su Lab, Scripps Research (collaborator)
  - Scientific collaboration partner
**Details**:
```yaml
type: Scientific Collaboration
status: Ongoing
partner: Su Lab, Scripps Research
```
